ZILRETTA in Subjects With Glenohumeral Osteoarthritis

Glenohumeral Osteoarthritis Clinical Trial

Official title:

A Phase 3, Multicenter, Randomized, Double-blind, Single-dose Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects With Glenohumeral Osteoarthritis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06269705
• Other study ID #: 006-C-301
• Status: Recruiting
• Phase: Phase 3
• Start date: February 5, 2024
• Est. completion date: August 2025

Study information

• Verified date: April 2024
• Source: Pacira Pharmaceuticals, Inc
• Contact: Jennifer Gordon
• Phone: 973-451-4055
• Email: jennifer.gordon[@]pacira.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: - To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, immediate release (TCA-IR) and normal saline placebo - To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline placebo and TCA-IR

Description:

This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of ZILRETTA in subjects with glenohumeral OA. This study will be conducted at approximately 25 study sites in the United States. Subjects will be screened to confirm the diagnosis of OA and eligibility based on the Inclusion and Exclusion Criteria. Approximately 250 male or female subjects, 50 to 80 years of age inclusive, will be enrolled, randomized to 1 of 3 treatment groups (2:2:1), and treated with a single IA injection of either: - Treatment Arm 1: 32 mg ZILRETTA, - Treatment Arm 2: 40 mg Immediate Release Triamcinolone (TCA-IR), or - Treatment Arm 3: placebo (normal saline). ZILRETTA, TCA-IR, or normal saline placebo will be administered as a single IA injection with a 24-week follow-up period with a primary endpoint at Week 12. The study will involve a Screening period (a minimum of 10 days, up to a maximum of 35 days), pre-treatment phase, dosing at Baseline/Day 1, and 8 additional outpatient visits at Weeks 2, 4, 8, 12, 16, 18, 20, and 24/EOS during the study. At specified times throughout the study, subjects will undergo physical examinations, index shoulder assessments, and index shoulder X-rays; blood will be collected for laboratory safety tests; and vital signs will be collected. Information regarding AEs and prior and concomitant medications and treatments will be collected from the time of signing the ICF through the Week 24/EOS visit. Information regarding rescue medication usage, Average and Worst daily Pain score in the index shoulder, and Sleep Interference (SI) will be completed daily via an electronic diary (eDiary) and reviewed for compliance by site staff at each study visit. At the Screening Visit, subjects will be registered in the eDiary and receive instructions on its use. Subjects will complete accurate pain reporting (APR) and placebo response reduction (PRR) training prior to completing all questionnaires.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: August 2025
• Est. primary completion date: August 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Written informed consent has been obtained prior to initiating any study-specific procedures.

2. Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions, including eDiary questionnaire completion requirements.

3. Subjects 50 to 80 years of age, inclusive, on the day of consent.

4. Body Mass Index (BMI) =40 kg/m2.

5. Symptoms (including pain) associated with OA of the index shoulder for =3 months prior to Screening Visit (subject self-report is acceptable).

6. Shoulder pain due to OA for >15 days over the last month (as reported by the subject).

7. Grade 2 or 3 OA in the index glenohumeral joint based on the Samilson-Prieto classification system as confirmed by X-ray (axillary view and true anterior-posterior view) taken at, or within 6 months of, the Screening Visit and read by the central reader.

8. Average daily mean pain score =4.0 and =9.0 in index shoulder (0-10 numeric rating scale [NRS]) using the average daily ratings for at least 4 out of the 7 days prior to Baseline/Day 1.

9. Average Shoulder Pain and Disability Index (SPADI) pain score =5.0 and =9.0 in index shoulder prior to Baseline/Day 1.

10. Willingness to abstain from use of protocol-specified restricted medications and therapies during the study.

11. Sexually active males or females of childbearing potential must agree to use a highly effective method of contraception throughout the duration of the study. Females of childbearing potential are defined as females who are not surgically sterile or postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause) as documented in medical history. Highly effective methods of contraception include abstinence; oral, injected, or implanted hormonal methods of contraception; intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or monogamous intercourse with a partner who is surgically sterile (post-vasectomy, -hysterectomy, or -tubal ligation). Exclusion Criteria: Disease-related criteria

1. Subjects who cannot washout of prohibited medications (eg, opioids, other analgesics, and THC- and cannabidiol (CBD)-containing products) or restricted medications.

2. Has symptomatic arthritis in other joints of the index shoulder (eg, acromioclavicular joint, sternoclavicular joint, or scapulothoracic joint), which is the primary source of pain in the opinion of the Investigator.

3. Has symptomatic rotator cuff pathology by physical examination or evidence of cuff tear arthropathy by radiograph.

4. Has clinical symptomatic chronic bilateral shoulder pain (any condition causing pain in the non- index shoulder).

5. Has a subchondral bone insufficiency fracture or humeral head necrosis/collapse (including bone infarct) in the index shoulder based on X-ray used for study qualification.

6. Has a prior ipsilateral proximal humerus fracture or scapula fracture to the index shoulder within 2 years of Screening Visit.

7. Has been diagnosed with adhesive capsulitis ("frozen shoulder") in the index shoulder, within 1 year of the Screening Visit.

8. Has a previous shoulder injury (eg, dislocation or clavicle fracture) in the index shoulder which resulted in functional limitation =1 month prior to the Screening Visit.

9. Prior surgery on the index shoulder (less than 5 years), either open or arthroscopic. Should not have any retained hardware.

10. Has an index shoulder with major dysplasia or congenital abnormality, osteochondritis dissecans, acromegaly, ochronosis, hemochromatosis, Wilson's disease, primary osteochondromatosis, chondrolysis from a pain pump, or a history of avascular necrosis with secondary OA.

11. Has current or history of infection (eg, osteomyelitis) in the index shoulder or current skin infection at injection site.

12. Has any concurrent chronic pain condition within 1 month prior to the Screening Visit (subject self- report acceptable), including but not limited to, cervical spine pain or conditions causing radicular pain or peripheral nerve injury/entrapment (eg, brachial plexus injury or suprascapular nerve entrapment); diabetic neuropathy; post-herpetic neuralgia; post-stroke pain; or fibromyalgia that may affect sensation of the index shoulder.

13. painDETECT Questionnaire (PD-Q) score >18 during Screening Visit.

14. History or current evidence of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease, systemic lupus erythematosus, or calcium pyrophosphate dihydrate crystal deposition (CPPD), gout, or other autoimmune diseases.

15. Any planned surgeries in the upper limbs and/or cervical spine during the study period, or any other surgery during the study period that would require use of a restricted medication. Previous or concomitant treatment-related criteria

16. Presence of surgical hardware or other foreign body due to open or arthroscopic cartilage transplant or bone grafting procedures in the index shoulder.

17. Use of muscle relaxants (eg, cyclobenzaprine, tetrazepam, and diazepam) and topical therapies (eg, NSAIDs, CBD oil, capsaicin, lidocaine patches, or other local treatments) applied to the index shoulder.

18. The use corticosteroids as follows:

• IA corticosteroid in the index shoulder within 3 months of Screening Visit.
• Intrabursal and intratendinous corticosteroids in the index shoulder within 6 months of Screening Visit.
• Intravenous (IV), Intramuscular (IM), or epidural corticosteroids within 6 months of Screening.
• Oral corticosteroids within 1 month of Screening.

19. IA treatment of index shoulder with any of the following agents within 6 months of Screening: hyaluronic acid (investigational or marketed) or any biologic agent (eg, platelet rich plasma [PRP] injection, stem cells, prolotherapy, and amniotic fluid-derived product).

20. Significant changes with regard to physical activity, physical therapy, or lifestyle within 1 month of the Screening Visit, or any planned changes throughout the duration of the study.

21. Use of selective serotonin/norepinephrine reuptake inhibitors (SSRIs/SNRIs) (eg, fluoxetine, fluvoxamine, citalopram, escitalopram, sertraline, duloxetine, and venlafaxine, milnacipran) if the dose is not stable for at least 3 months prior to Screening Visit and must remain stable throughout the study.

22. Any treatment with acupuncture and/or transcutaneous electrical nerve stimulation (TENS) within 3 months of Screening Visit. Subject-related criteria

23. Females who are pregnant or nursing or plan to become pregnant within 12 months after dosing; men whose partner plans to conceive within 12 months after dosing.

24. Subjects with clinically relevant level of pain catastrophizing defined as Pain Catastrophizing Scale (PCS) score of =30 at Screening Visit.

25. Known or suspected hypersensitivity to any form of triamcinolone or PLGA.

26. Laboratory evidence of infection with human immunodeficiency virus (HIV), positive test for hepatitis B surface antigen (HBsAg), or positive serology for hepatitis C virus (HCV) with positive test for HCV ribonucleic acid (RNA) on recent testing.

27. A medical history suggesting the subject will or is likely to require a course of systemic corticosteroids during the study.

28. History or evidence of active or latent systemic fungal or mycobacterial infection (including tuberculosis) or of ocular herpes simplex.

29. History of sarcoidosis, amyloidosis or active Cushing's syndrome.

30. Use of immunomodulators, immunosuppressives, or chemotherapeutic agents within 5 years of Screening.

31. Active or history of malignancy within 5 years of Screening, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or effectively managed cervical carcinoma.

32. History of radiation treatment involving the index shoulder girdle.

33. Active substance abuse (drugs or alcohol) or history of substance abuse within the past 12 months of Screening.

34. Has received a live vaccine within 3 months of Baseline/Day 1.

35. Has received vaccination within 1 week prior to the Screening Visit and local injection pain has not resolved.

36. Use of any other investigational drug, biologic, or device within 3 months of Screening Visit.

37. Any bacterial or viral infection requiring IV antibiotics within 4 weeks of Baseline/Day 1 or oral antibiotics within 2 weeks of Baseline/Day 1.

38. Any other clinically significant acute or chronic medical conditions (eg, poorly controlled diabetes with hemoglobin A1c [HbA1c] of greater than 9.5%) that, in the judgment of the Investigator, could compromise subject safety, preclude the use of an IA corticosteroid, limit the subject's ability to complete the study, or compromise the objectives of the study.

39. Subjects contraindicated to the use of acetaminophen/paracetamol (allowed rescue pain medicine) per National Product Labeling and Investigator's judgment.

40. Investigator or any subinvestigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof directly involved in the conduct of the study.

Related Conditions & MeSH terms

• Glenohumeral Osteoarthritis
• Osteoarthritis

Intervention

Drug:
• ZILRETTA
IA injection of 32 mg ZILRETTA
• TCA-IR
IA injection of 40 mg TCA-IR

Other:
• Placebo
IA injection of placebo (normal saline)

Locations

Country	Name	City	State
United States	Alabama Orthopaedic Center- Research	Birmingham	Alabama

Sponsors (1)

Lead Sponsor	Collaborator
Pacira Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 12 for ZILRETTA relative to placebo		Week 12
Secondary	Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 12 for ZILRETTA relative to TCA-IR		Week 12
Secondary	Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 18 for ZILRETTA relative to TCA-IR		Week 18
Secondary	Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 2 for ZILRETTA relative to placebo		Week 2
Secondary	Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 4 for ZILRETTA relative to placebo		Week 4
Secondary	Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 8 for ZILRETTA relative to placebo		Week 8
Secondary	Change from Baseline at Week 12 on the SPADI total score and subscales for ZILRETTA relative to placebo		Week 12
Secondary	Change from Baseline at Week 12 on the SPADI total score and subscales for ZILRETTA relative to TCA-IR		Week 12